RxDoctor Payments Data

Ashish Patel, MD

Internal Medicine · Richmond, KYNPI 1811915598

Payments from drug & device makers

$1,244in general payments, 2019–2025

Across 81 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$263
  • Astellas Pharma US Inc$166
  • Lilly USA, LLC$164
  • Amgen$121
  • AbbVie$75
  • GSK$71
  • plus $385 from 15 others

What the payments were for

  • Food & beverage$1,22999%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,244 in reported general payments places this provider in the 65th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,619
Medicare patients
151
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$144,867
OzempicSemaglutide98$107,736
JardianceEmpagliflozin37$50,757
JanuviaSitagliptin Phosphate33$34,809
XareltoRivaroxaban28$31,729
MounjaroTirzepatide13$21,526
JanumetSitagliptin Phos/Metformin Hcl13$20,485
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$10,493
MyrbetriqMirabegron15$9,725
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$9,694
Breo ElliptaFluticasone/Vilanterol12$8,522
Atorvastatin Calcium665$6,083
Levothyroxine Sodium392$5,069
Humalog Kwikpen U-100Insulin Lispro17$4,795
Novolog FlexpenInsulin Aspart14$4,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$263$144,867128 claims
Novo NordiskOzempic$47$107,73698 claims
Boehringer IngelheimJardiance$15$50,75737 claims
Johnson & JohnsonXarelto$31$31,72928 claims
Lilly USA, LLCMounjaro$164$21,52613 claims
Astellas Pharma US IncMyrbetriq$166$9,72515 claims
GSKBreo Ellipta$71$8,52212 claims
AstraZenecaSymbicort$34$3,70511 claims
AbbVieSynthroid$75$2,01264 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Richmond

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →